摘要
Enterovirus A71 (EV-A71) is a major causative agent of hand, foot, and mouth disease (HFMD) and herpangina. Moreover, EV-A71 infection can lead to neurological complications and death. Vaccination is the most efficient way to control virus infection. There are currently three inactivated, whole EV-A71 vaccines licensed by the China NMPA (National Medical Products Administration). Several other types of vaccines, such as virus-like particles and recombinant VP1 (capsid protein), are also under development. In this review, we discuss recent advances in the development of EV-A71 vaccines.
原文 | 英語 |
---|---|
文章編號 | 199 |
頁(從 - 到) | 1-10 |
頁數 | 10 |
期刊 | Vaccines |
卷 | 9 |
發行號 | 3 |
DOIs | |
出版狀態 | 已出版 - 2021 |
文獻附註
Publisher Copyright:© 2021 by the authors. Licensee MDPI, Basel, Switzerland.